Immunomagnetic Reduction Detects Plasma Aβ_1-42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline

Area of Science:

• Neuroscience
• Biochemistry
• Medical Diagnostics

Background:

• Alzheimer's disease (AD) biomarkers like Aβ_1-40, Aβ_1-42, and tau are present at very low concentrations in human plasma.
• Ultrasensitive assays, such as immunomagnetic reduction (IMR), enable precise quantification of these low-concentration biomarkers.

Purpose of the Study:

• To review and compare the significance of plasma biomarkers (Aβ_1-40, Aβ_1-42, tau) in predicting cognitive decline.
• To focus on patient cohorts including Down syndrome, stroke, and amnestic mild cognitive impairment (MCI).

Main Methods:

• Literature review of studies utilizing ultrasensitive assays, specifically IMR.
• Analysis of findings related to plasma biomarker concentrations and their correlation with cognitive decline in specific patient groups.

Main Results:

• Review articles confirm the feasibility of detecting early-stage AD using plasma biomarkers with IMR.
• Plasma Aβ_1-42 emerged as a potentially predominant biomarker for predicting cognitive decline across the studied patient groups.

Conclusions:

• Plasma Aβ_1-42 holds significant potential as a predictive biomarker for cognitive decline in diverse neurological conditions.
• Ultrasensitive assays like IMR are crucial for advancing the detection and monitoring of neurodegenerative diseases through plasma biomarkers.